Protokinetix, Inc. (PKTX) Stock Price & Analysis
Protokinetix, Inc. (PKTX) rose 3.13% to USD 0.01 as of July 25, 2026 at 05:30 UTC, according to Nexqual real-time market data.
PKTX last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 2,962 shares. Market capitalization is $2.58M, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, July 25, 2026 at 05:30 UTC.
Key Statistics (as of July 25, 2026 at 05:30 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 3.13% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 2,962 shares |
| Market Cap | $2.58M |
| Exchange | PNK |
Technical Analysis (PKTX)
Nexqual's technical model rates PKTX "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of July 25, 2026 at 05:30 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.3 (neutral) |
| vs SMA50 | Above (USD 0.01) |
| MACD | 0 (positive) |
Analyst Ratings (PKTX)
Wall Street analysts rate PKTX "None", per Nexqual as of July 25, 2026 at 05:30 UTC.
| Consensus Rating | None |
|---|
Earnings (PKTX)
Source: Nexqual, July 25, 2026 at 05:30 UTC.
Financials & Fundamentals (PKTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -117.19% |
| Current Ratio | 0.01 |
| Total Cash | $607 |
| Total Debt | $0 |
| Free Cash Flow | $-81,407 |
Source: Nexqual, July 25, 2026 at 05:30 UTC.
Financial Health Score (PKTX)
Nexqual rates Protokinetix, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:30 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $607 cash, no debt |
| Cash Flow | Weak — Operating cash flow -$181K |
| Efficiency | Critical — ROE -117%, ROA -49.1% |
Ownership (PKTX)
| Insider Ownership | +37.68% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 391.58M |
| Float | 323.67M |
Source: Nexqual, July 25, 2026 at 05:30 UTC.
Leadership (PKTX)
Protokinetix, Inc. is led by Michael Richard Guzzetta (age 67), Chairman, CEO, CFO, Treasurer & Secretary, per Nexqual as of July 25, 2026 at 05:30 UTC.
| Chairman, CEO, CFO, Treasurer & Secretary | Michael Richard Guzzetta (age 67) |
|---|---|
| President & Director | Keith R. Brunt (age 46) |
From Protokinetix, Inc.'s Latest SEC 10-K Filing (filed 2025-03-28)
Key Strengths & Strategy (as disclosed to the SEC)
- ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).
- Its AFGPs are used in various commercial applications comprising targeted health care solutions, as well as AAGPs are used for applications in ophthalmology, dermatology, transplants, and biomanufacturing areas.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MYMX | MYMETICS CORPORATION | USD 0 | ▲ 0% |
| BIOAF | BIOASIS TECHNOLOGIES INC | USD 0 | ▲ 0% |
| BETRF | BETTERLIFE PHARMA INC. | USD 0.15 | ▼ 13.45% |
| NUMD | Nu-Med Plus Inc. | USD 0.02 | ▲ 21.05% |
| ZHCLF | Zenith Cap Corp. | USD 0.05 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:30 UTC. This page is informational and not investment advice.